Abstract
Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.
Original language | English |
---|---|
Journal | Internal Medicine Journal |
DOIs | |
Publication status | Accepted/In press - 2024 |
Keywords
- asciminib
- chronic myeloid leukaemia
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Internal Medicine